New York, May 28, 2026, 04:16 EDT
Krystal Biotech (KRYS) was poised to start Thursday trade just below its 52-week high. A fresh SEC filing showed EVP and general counsel Thomas John Charles sold a small batch of shares using a preset trading plan. KRYS last traded at $306.63, above the midpoint of its $123.03 to $319.48 range for the past year.
U.S. markets stayed open. Nasdaq’s 2026 calendar shows markets closed for Memorial Day on May 25 and Juneteenth on June 19. Thursday lands on a normal trading day after the short week.
Krystal’s stock run has made even standard insider filings a focus for traders. The rare-disease gene therapy company was last valued around $9.35 billion.
Charles sold 642 shares at $302.03 on May 26, according to a Form 4 filing from May 27. After the sale, he had no directly held common shares left. The trades were made under a Rule 10b5-1 plan adopted Feb. 23, letting insiders set stock sales ahead of time, the filing said.
The deal wasn’t big in balance-sheet terms, at about $193,900 according to the filing. But insider selling tends to stand out for a biotech name trading near its high, especially with investors watching for clinical updates.
VYJUVEK is still the main story for Krystal, the biotech’s topical gene therapy for DEB, a rare disease that makes skin fragile and prone to blisters. Earlier this month, Krystal said VYJUVEK net product revenue jumped 32% to $116.4 million in the first quarter. Gross margin was 95%. Net income hit $55.9 million. CEO Krish S. Krishnan called out “strong momentum” as the company looks for upcoming study data and rolls out VYJUVEK abroad. Krystal Biotech, Inc.
The FDA signed off on VYJUVEK in 2023, clearing it for wounds in patients at least six months old with DEB caused by mutations in the COL7A1 gene. According to the agency, DEB happens when a genetic defect weakens type VII collagen—the protein that keeps skin layers together.
Krystal is readying for more data. The company said it expects to see two registrational readouts this year, with late-stage results for KB803 in DEB corneal abrasions and KB801 in neurotrophic keratitis, a condition where nerve damage stops healing in the eye’s surface. R&D chief Suma Krishnan said, “two registrational study readouts later this year.” In Europe, rollout of VYJUVEK is going “market by market, physician by physician, and patient by patient,” according to Europe lead Laurent Goux. MarketBeat
KRYS has analysts mostly positive but divided. The consensus price target is $276.57 across 15 analysts, according to Benzinga, which trails the most recent KRYS price. Citigroup is at the high end with a $378 target, while H.C. Wainwright’s latest rating pegs it at $310.
Competition is tight in the space. Abeona Therapeutics got FDA approval for Zevaskyn, a cell-based gene therapy for recessive DEB, in 2025. Reuters said Krystal’s VYJUVEK is on the market for smaller wounds. Jefferies analyst Maury Raycroft sees Zevaskyn hitting $427 million in peak sales by 2034. Brett Kopelan, executive director at debra of America, told Reuters these therapies together could “hopefully make this disease chronic but livable.” Reuters
Chiesi’s Filsuvez is on the market as a treatment for wounds in epidermolysis bullosa. The drug’s FDA label covers wounds tied to dystrophic and junctional epidermolysis bullosa in patients as young as six months.
Biotech stocks were steady late Wednesday, with the iShares Nasdaq Biotechnology ETF up $0.52 at $169.88 and the SPDR S&P Biotech ETF gaining $1.13 to $134.45. Krystal is getting some help from the sector, but the stock’s trading is still mostly about VYJUVEK sales and when new data lands, not just the ETF moves.
But the current setup means there’s less room if there are delays or weak data. Shares could come under pressure if KB801 or KB803 stumble, if reimbursement decisions in Europe take longer, if VYJUVEK maintenance demand softens, or if Abeona and Chiesi get more competitive. Krishnan told analysts that it’s “fairly tough to predict the ups and downs” in quarterly VYJUVEK revenue. MarketBeat
Krystal has a profitable approved product, a strong market value, and investors are watching its late-year pipeline. The story is straightforward for now.
